July 30, 2018
By Shana K. Cyr, Ph.D.; Susan Y. Tull
Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to intellectual property protection often follow. In this series, we take a close look at IP considerations that SaMD developers should be aware of as they enter this market. In this podcast, Finnegan partners Shana Cyr and Susan Tull explore the interplay between intellectual property and Food and Drug Administration (FDA) submissions for SaMD.
software as a medical device (SaMD), Food and Drug Administration (FDA), Podcast Series: Software as a Medical Device (SaMD)
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.